-
July 3, 2023 Australia Becomes the First Country to Prescribe Psychedelics to Treat Depression and PTSDAustralia has become the first country to prescribe MDMA to treat PTSD and psilocybin to...
-
June 1, 2023 The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked OffThe largest Phase 3 clinical trial investigating the efficacy and tolerability of psilocybin for treatment-resistant...
-
May 30, 2023 Single Dose of Psilocybin Yields Long-Term Depression Remission in Over 50% of Cancer PatientsA single 25mg dose of psilocybin paired with psychological support has resulted in 57% of...
-
March 16, 2023 ‘Right To Try Laws’ and Legal Access to Psilocybin Therapy with Dr. Jonathan FieldsPetitioning the DEA to respect the ‘Right to Try Laws’ which empower terminally ill patients...
-
November 3, 2022 Compass Pathways Phase 2 Psilocybin Results far from SpectacularPsilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed...
-
October 17, 2022 Math Over Myth: Compass and Revive Release Phase 3 Updates but Stocks DropMath over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and...
-
September 9, 2022 Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASSIf you want to invest in psychedelic stocks, ignore the hype and look at the...
-
September 7, 2022 Psychedelic Stocks: ARK Invest and the Reverse Midas TouchCathie Wood is buying up stocks from the most dubious actors in the psychedelic sector....
-
August 10, 2022 Compass Pathways Sued for Stealing Trade SecretsCompass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual...
-
August 8, 2022 Three Phase 3 Clinical Trials that Could Legalize PsychedelicsThe road to psychedelic legalization has many paths. These 3 clinical trials have the best...
